These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 19763601)

  • 1. Predictive factors for changes in macular edema in intravitreal bevacizumab therapy of retinal vein occlusion.
    Ach T; Hoeh AE; Schaal KB; Scheuerle AF; Dithmar S
    Graefes Arch Clin Exp Ophthalmol; 2010 Feb; 248(2):155-9. PubMed ID: 19763601
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term follow-up of OCT-guided bevacizumab treatment of macular edema due to retinal vein occlusion.
    Hoeh AE; Ach T; Schaal KB; Scheuerle AF; Dithmar S
    Graefes Arch Clin Exp Ophthalmol; 2009 Dec; 247(12):1635-41. PubMed ID: 19633982
    [TBL] [Abstract][Full Text] [Related]  

  • 3. OCT patterns of macular edema and response to bevacizumab therapy in retinal vein occlusion.
    Hoeh AE; Ruppenstein M; Ach T; Dithmar S
    Graefes Arch Clin Exp Ophthalmol; 2010 Nov; 248(11):1567-72. PubMed ID: 20596719
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictive factors for functional improvement after intravitreal bevacizumab therapy for macular edema due to branch retinal vein occlusion.
    Jaissle GB; Szurman P; Feltgen N; Spitzer B; Pielen A; Rehak M; Spital G; Heimann H; Meyer CH;
    Graefes Arch Clin Exp Ophthalmol; 2011 Feb; 249(2):183-92. PubMed ID: 21337042
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effects of intravitreal bevacizumab on patients with macular edema secondary to branch retinal vein occlusion.
    Ahmadi AA; Chuo JY; Banashkevich A; Ma PE; Maberley DA
    Can J Ophthalmol; 2009 Apr; 44(2):154-9. PubMed ID: 19491948
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Short term results of intra-vitreal bevacizumab for the treatment of macular edema secondary to retinal vein occlusion.
    Thapa R; Poudyal G
    Nepal J Ophthalmol; 2013; 5(1):63-8. PubMed ID: 23584649
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravitreal triamcinolone acetonide versus bevacizumab therapy for macular edema associated with branch retinal vein occlusion.
    Byun YJ; Roh MI; Lee SC; Koh HJ
    Graefes Arch Clin Exp Ophthalmol; 2010 Jul; 248(7):963-71. PubMed ID: 20182882
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravitreal bevacizumab treatment of macular edema in central retinal vein occlusion: one-year results.
    Beutel J; Ziemssen F; Lüke M; Partsch M; Bartz-Schmidt KU; ; Gelisken F
    Int Ophthalmol; 2010 Feb; 30(1):15-22. PubMed ID: 19099203
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The influence of anti-VEGF therapy on present day management of macular edema due to BRVO and CRVO: a longitudinal analysis on visual function, injection time interval and complications.
    Papadia M; Misteli M; Jeannin B; Herbort CP
    Int Ophthalmol; 2014 Dec; 34(6):1193-201. PubMed ID: 25245600
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of intravitreal bevacizumab upload followed by a dexamethasone implant versus dexamethasone implant monotherapy for retinal vein occlusion with macular edema.
    Mayer WJ; Remy M; Wolf A; Kook D; Kampik A; Ulbig M; Reznicek L; Haritoglou C
    Ophthalmologica; 2012; 228(2):110-6. PubMed ID: 22739239
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical, anatomical, and electrophysiological assessments of the central retina following intravitreal bevacizumab for macular edema secondary to retinal vein occlusion.
    Loukianou E; Brouzas D; Chatzistefanou K; Koutsandrea C
    Int Ophthalmol; 2016 Feb; 36(1):21-36. PubMed ID: 25820576
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical, anatomic, and electrophysiologic evaluation following intravitreal bevacizumab for macular edema in retinal vein occlusion.
    Pai SA; Shetty R; Vijayan PB; Venkatasubramaniam G; Yadav NK; Shetty BK; Babu RB; Narayana KM
    Am J Ophthalmol; 2007 Apr; 143(4):601-6. PubMed ID: 17306753
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of intravitreal bevacizumab for macular edema following branch retinal vein occlusion stratified by baseline visual acuity.
    Kim M; Jeong S; Sagong M
    Graefes Arch Clin Exp Ophthalmol; 2017 Apr; 255(4):691-697. PubMed ID: 27796671
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Predictive Value of OCT-Controlled Early Response of Macular Edema Secondary to Retinal Vein Occlusion After Intravitreal Bevacizumab Therapy].
    Kourakos V; Rauscher A; Schmidbauer J
    Klin Monbl Augenheilkd; 2019 Oct; 236(10):1215-1222. PubMed ID: 29642262
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictive factors for functional improvement following intravitreal bevacizumab injections after central retinal vein occlusion.
    Januschowski K; Feltgen N; Pielen A; Spitzer B; Rehak M; Spital G; Dimopoulos S; ; Meyer CH; Szurman GB
    Graefes Arch Clin Exp Ophthalmol; 2017 Mar; 255(3):457-462. PubMed ID: 27632214
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Macular cystic changes as predictive factor for the recurrence of macular oedema in branch retinal vein occlusion.
    Tilgner E; Dalcegio Favretto M; Tuisl M; Wiedemann P; Rehak M
    Acta Ophthalmol; 2017 Nov; 95(7):e592-e596. PubMed ID: 28266152
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prolongation of activity of single intravitreal bevacizumab by adjuvant topical aqueous depressant (Timolol-Dorzolamide).
    Byeon SH; Kwon OW; Song JH; Kim SE; Park YS
    Graefes Arch Clin Exp Ophthalmol; 2009 Jan; 247(1):35-42. PubMed ID: 18682969
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravitreal bevacizumab (Avastin) for macular oedema secondary to retinal vein occlusion: 12-month results of a prospective clinical trial.
    Prager F; Michels S; Kriechbaum K; Georgopoulos M; Funk M; Geitzenauer W; Polak K; Schmidt-Erfurth U
    Br J Ophthalmol; 2009 Apr; 93(4):452-6. PubMed ID: 19074916
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bevacizumab treatment of macular edema in CRVO and BRVO: long-term follow-up. (BERVOLT study: Bevacizumab for RVO long-term follow-up).
    Kornhauser T; Schwartz R; Goldstein M; Neudorfer M; Loewenstein A; Barak A
    Graefes Arch Clin Exp Ophthalmol; 2016 May; 254(5):835-44. PubMed ID: 26269374
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Bevacizumab for the treatment of macular edema secondary to retinal vein occlusion].
    Schaal KB; Höh AE; Scheuerle A; Schütt F; Dithmar S
    Ophthalmologe; 2007 Apr; 104(4):285-9. PubMed ID: 17372737
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.